Acumen Pharmaceuticals, Inc.

Forging a new path towards a safe and effective treatment for Alzheimer’s disease.

Add To Watchlist
General Information
Company Name
Acumen Pharmaceuticals, Inc.
Founded Year
1996
Location (Offices)
Charlottesville, United States +3
Founders / Decision Makers
Daniel J. O'Connell - Director, President & CEO Daniel O'Connell - President & Chief Executive Officer
Number of Employees
66
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Post Ipo Debt
Social Media

Acumen Pharmaceuticals, Inc. - Company Profile

Acumen Pharmaceuticals, Inc. is a biotechnology startup founded in 1996 and based in the United States. The company is dedicated to forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases. Their focus on the biology of toxic soluble amyloid-beta oligomers sets them apart in the industry. The founders have made seminal discoveries and developed methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. This invaluable expertise has fueled decades of research on the biology of Aβo at Acumen and across the field. With a $50.00M post-IPO debt investment from K2 HealthVentures as of 13 November 2023, Acumen Pharmaceuticals is on the cusp of realizing the therapeutic potential of Aβo targeted drugs. Their bold vision and groundbreaking research make them a promising player in the biotechnology sector.

Taxonomy: Alzheimer's disease, neurodegenerative disease, therapeutics, amyloid-beta oligomers, monoclonal antibodies, immunotherapy, clinical-stage biopharmaceutical, drug development, biological research, targeted immunotherapy, ACU193, Phase 1 clinical trial, toxic soluble oligomers, neuroscience, disease-modifying approach

Funding Rounds & Investors of Acumen Pharmaceuticals, Inc. (7)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Debt $50.00M 1
K2 HealthVentures, investor in Acumen Pharmaceuticals, Inc.'s Post-IPO Debt round
13 Nov 2023
Post-IPO Equity $130.00M - 17 Jul 2023
Series B $75.00M 5
RA Capital Management, investor in Acumen Pharmaceuticals, Inc.'s Series B round BlackRock, investor in Acumen Pharmaceuticals, Inc.'s Series B round Sands Capital Ventures, investor in Acumen Pharmaceuticals, Inc.'s Series B round PBM Capital, investor in Acumen Pharmaceuticals, Inc.'s Series B round Rock Springs Capital, investor in Acumen Pharmaceuticals, Inc.'s Series B round
20 Nov 2020
Series A $15.00M 2
Sands Capital Ventures, investor in Acumen Pharmaceuticals, Inc.'s Series A round PBM Capital, investor in Acumen Pharmaceuticals, Inc.'s Series A round
24 Oct 2018
Grant $3.60M 1 National Institute on Aging 28 Jul 2017

View All 7 Funding Rounds

Latest News of Acumen Pharmaceuticals, Inc.

View All

No recent news or press coverage available for Acumen Pharmaceuticals, Inc..

Similar Companies to Acumen Pharmaceuticals, Inc.

View All
AltPep - Similar company to Acumen Pharmaceuticals, Inc.
AltPep AltPep develops early disease-modifying treatments and detection tools for amyloid diseases.
Alzinova AB - Similar company to Acumen Pharmaceuticals, Inc.
Alzinova AB Swedish clinical stage biopharma company developing disease-modifying treatments against Alzheimer's disease.
Cognoptix - Similar company to Acumen Pharmaceuticals, Inc.
Cognoptix The Eye Scan for Alzheimer's Early Insight
Attralus - Similar company to Acumen Pharmaceuticals, Inc.
Attralus Attralus is a biopharmaceutical company creating transformative medicines for patients with systemic amyloidosis.
Araclon Biotech, S.L. - Similar company to Acumen Pharmaceuticals, Inc.
Araclon Biotech, S.L. La ciencia si no es honesta, no es ciencia. Dr. Manuel Sarasa.
Circle Decoration Circle Decoration

Want to dive deeper into Acumen Pharmaceuticals, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now